{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-294899","form_type":"8-K","ticker":"SYRE","cik":"0001636282","company_name":"Spyre Therapeutics, Inc.","filed_at":"2022-11-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.519720+00:00","generated_at":"2026-06-21T11:42:21.371271+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aeglea Biotherapeutics appoints Jeffrey M. Goldberg as President and CEO","bullets":["Jeffrey M. Goldberg appointed President, CEO, and Class III director effective Nov 29, 2022.","Jim Kastenmayer resigns as Interim CEO, remains General Counsel and Corporate Secretary.","Goldberg receives $600k base salary, up to 50% cash bonus, and $35k housing allowance.","Stock option for 1,884,838 shares granted, vesting 1/4 on first anniversary then monthly."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-294899","json":"https://secwatch.observer/filing/0001193125-22-294899.json","markdown":"https://secwatch.observer/filing/0001193125-22-294899.md","text":"https://secwatch.observer/filing/0001193125-22-294899.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000119312522294899/0001193125-22-294899-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000119312522294899/d376158d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T11:42:21.371271+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1496aa43fd","claim":"Jeffrey M. Goldberg was appointed as President and Chief Executive Officer at Spyre Therapeutics, Inc..","evidence_excerpt":"On November 28, 2022, the board of directors (the “Board”) of Aeglea Biotherapeutics, Inc. (the “Company”) appointed Jeffrey M. Goldberg, age 50, as President and Chief Executive Officer, and as a Class III director, effective November 29, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000119312522294899/0001193125-22-294899-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"96eded69c0","claim":"Jim Kastenmayer resigned as General Counsel and Corporate Secretary at Spyre Therapeutics, Inc..","evidence_excerpt":"In conjunction with the appointment of Mr. Goldberg, Jim Kastenmayer resigned from his position as the Company’s Interim Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000119312522294899/0001193125-22-294899-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"General Counsel and Corporate Secretary"}],"fact_type":"executive_change"},{"claim_id":"c095a3dffe","claim":"Jeffrey M. Goldberg was appointed as Class III director at Spyre Therapeutics, Inc..","evidence_excerpt":"On November 28, 2022, the board of directors (the “Board”) of Aeglea Biotherapeutics, Inc. (the “Company”) appointed Jeffrey M. Goldberg, age 50, as President and Chief Executive Officer, and as a Class III director, effective November 29, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000119312522294899/0001193125-22-294899-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}